- Raw materials
- Anti-infective Agents
- Dichlorvos
Dimethyl ester (Dichlorvos) API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Dichlorvos | CAS No: 62-73-7 | GMP-certified suppliers
A medication that serves as a potent antiparasitic and insecticidal agent for controlling indoor pests and protecting stored agricultural products from insect infestation.
Therapeutic categories
Product Snapshot
- Dichlorvos is formulated as an organophosphate insecticide primarily used in veterinary applications
- Its main therapeutic use includes controlling parasitic infestations in animals
- The product holds veterinary approval status without indications of human pharmaceutical regulatory approvals
Clinical Overview
Its primary mechanism of action is through irreversible inhibition of acetylcholinesterase, an enzyme essential for terminating synaptic transmission by hydrolyzing the neurotransmitter acetylcholine. This inhibition leads to an accumulation of acetylcholine at nerve synapses and neuromuscular junctions, resulting in continuous nerve impulse transmission, paralysis, and ultimately the death of target insects. This cholinesterase inhibitory property categorizes dichlorvos alongside other organophosphorus compounds noted for their neurotoxic activity.
Although widely used in agricultural and veterinary contexts, dichlorvos has no direct clinical indication for human therapeutic use. Its toxicological profile is significant; exposure can cause acute poisoning characterized by cholinergic symptoms, neurotoxicity, and long-term health risks including carcinogenic potential. Environmental persistence poses concerns, with dichlorvos residues detected in urban waterways. The compound is considered a potential QTc-prolonging agent and thus requires careful management regarding human exposure routes.
Key pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized in humans due to its primary use as a pesticide and associated toxicity. In veterinary applications, there is regulated approval for use, acknowledging the extreme care necessary in handling and application.
For API sourcing and procurement, stringent quality controls are essential to ensure purity and limit contamination by related organophosphate impurities. Suppliers must comply with international regulatory standards for agrochemical APIs, including thorough documentation of manufacturing processes and batch consistency, to minimize risks of environmental contamination and human exposure during handling and formulation.
Identification & chemistry
| Generic name | Dichlorvos |
|---|---|
| Molecule type | Small molecule |
| CAS | 62-73-7 |
| UNII | 7U370BPS14 |
| DrugBank ID | DB11397 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Serotransferrin | Humans | |
| Cholinesterase | Humans |
Formulation & handling
- Dichlorvos is a small molecule suitable primarily for oral formulations due to its moderate water solubility. The compound's moderate LogP value suggests balanced lipophilicity for absorption but requires careful solvent selection in formulation. Stability considerations include protection from hydrolysis and light exposure to maintain compound integrity.
Regulatory status
Dichlorvos is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
